The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) gapped down by $0.07 today and has $22.56 target or 5.00% below today’s $23.75 share price. The 7 months technical chart setup indicates high risk for the $1.18B company. The gap down was reported on Oct, 4 by Barchart.com. If the $22.56 price target is reached, the company will be worth $59.00M less.
Gaps down are helpful for identifying a resistance level and to could also be used as a tradeable event. If traders are short the stock and it experiece gap down, then its usually advisable to hold the short for a bigger down move. Back-tests of such patterns show that two-thirds of the these patterns the stock performance worsens after the gap. The area gaps close 91% of the time, the breakaway gaps 1%, the continuation gaps 9% and the exhaustion gaps 64%. The stock decreased 3.96% or $0.98 during the last trading session, hitting $23.75. About 1.05M shares traded hands or 55.35% up from the average. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has risen 82.97% since March 1, 2016 and is uptrending. It has outperformed by 70.76% the S&P500.
Analysts await Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to report earnings on November, 1. They expect $0.21 earnings per share, up 162.50% or $0.13 from last year’s $0.08 per share. SUPN’s profit will be $10.43 million for 28.27 P/E if the $0.21 EPS becomes a reality. After $0.18 actual earnings per share reported by Supernus Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 16.67% EPS growth.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Ratings Coverage
Out of 3 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Supernus Pharmaceuticals has been the topic of 6 analyst reports since August 26, 2015 according to StockzIntelligence Inc. The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has “Market Perform” rating given on Monday, July 18 by Northland Capital. The firm has “Outperform” rating by Northland Capital given on Thursday, November 5. The stock has “Buy” rating given by Jefferies on Thursday, August 4. Piper Jaffray downgraded the stock to “Neutral” rating in Monday, July 18 report. The firm has “Outperform” rating given on Wednesday, October 28 by Northland Capital. The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has “Hold” rating given on Wednesday, August 26 by Zacks.
According to Zacks Investment Research, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.”
Insitutional Activity: The institutional sentiment increased to 1.26 in 2016 Q2. Its up 0.11, from 1.15 in 2016Q1. The ratio increased, as 27 funds sold all Supernus Pharmaceuticals Inc shares owned while 62 reduced positions. 25 funds bought stakes while 87 increased positions. They now own 45.62 million shares or 4.54% more from 43.64 million shares in 2016Q1.
Louisiana State Employees Retirement Systems holds 15,300 shares or 0.02% of its portfolio. Nicholas Investment Prtnrs L P holds 136,776 shares or 0.19% of its portfolio. Pacad Inv Ltd has 17,891 shares for 0.05% of their US portfolio. Allianz Asset Ag reported 375,424 shares or 0% of all its holdings. Kopp Investment Advsrs Ltd Limited Liability Company holds 0.52% or 47,884 shares in its portfolio. White Pine last reported 43,100 shares in the company. Northern Trust has 0% invested in the company for 646,452 shares. Cadence Mngmt Llc owns 50,260 shares or 0.08% of their US portfolio. Cubist Systematic Strategies Lc holds 12,480 shares or 0.01% of its portfolio. Pinebridge Invs Lp holds 0% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 4,388 shares. Goldman Sachs Grp Incorporated accumulated 38,414 shares or 0% of the stock. Pnc Fincl Grp Incorporated, a Pennsylvania-based fund reported 22,996 shares. First Dallas Secs owns 11,250 shares or 0.18% of their US portfolio. Moreover, New York State Teachers Retirement has 0% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 69,020 shares. Bank Of New York Mellon last reported 1.66 million shares in the company.
Insider Transactions: Since April 11, 2016, the stock had 0 buys, and 2 selling transactions for $557,228 net activity. Shares for $50,000 were sold by PATRICK GREGORY S on Friday, September 16. The insider Bhatt Padmanabh P. sold 30,762 shares worth $507,228.
More recent Supernus Pharmaceuticals Inc (NASDAQ:SUPN) news were published by: Fool.com which released: “Supernus Pharmaceuticals Is Dropping — Is It a Buy?” on November 12, 2015. Also Prnewswire.com published the news titled: “Supernus Pharmaceuticals Founder and CEO Jack Khattar joins scPharmaceuticals …” on July 12, 2016. Reuters.com‘s news article titled: “BRIEF-Supernus pharmaceuticals Inc says FY 2016 net product sales will rem…” with publication date: August 02, 2016 was also an interesting one.
SUPN Company Profile
Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a pharmaceutical firm focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Firm offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It is also engaged in developing multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). The Company’s psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is also developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. The Firm markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.